Janssen Pharmaceutical has updated the Phase 3 MACiTEPH study, which evaluates macitentan 75mg in patients with Chronic Thromboembolic...

Bayer presented the long-term studies of Xarelto in patients with coronary artery disease and/or peripheral artery disease. Bayer has...